Jessica Alston, Ph.D.
Partner
About
Jessica is a Partner at F-Prime Capital and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents.
Jessica holds a Ph.D. in genetics from Harvard University and received her BS in biology from Duke University, graduating summa cum laude.
-
Adela (formerly DNAMx) is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylation analysis technology has the unique ability to distinguish the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially target those informative regions for sequencing. Learn more at www.adelabio.com.
-
Category
- MedTech
-
Status
- Private
-
Location
Toronto, Ontario
-
Year Invested
2021
-
Team
-
-
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. Learn more at www.atalantatx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Boston, MA
-
Year Invested
2019
-
Team
-
-
Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time. Learn more at www.beamtx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Cambridge, MA
-
Year Invested
2018
-
Team
-
-
BioPalette is a life science start up formed out of Kobe University developing base editing technology for a range of applications. Learn more at www.biopalette.co.jp.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Kobe, Japan
-
Year Invested
2017
-
Team
-
-
Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to lower the risks of pregnancy and premature births worldwide. We are currently developing the world’s first treatment for preeclampsia, which affects more than 10 million women every year. Learn more at www.comanchebiopharma.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Concord, MA
-
Year Invested
2021
-
Team
-
-
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. learn more at www.invetx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Boston, MA
-
Year Invested
2022
-
Team
-
-
LunaDNA is the first health and genomic data platform owned by its community of personal health information donors. LunaDNA empowers individuals to share their health data for medical research and the greater good of the community. As community owners in the LunaDNA platform, members share in the value created from health discoveries and medical breakthroughs. LunaDNA was created by the privately-owned Public Benefit Corporation, LunaPBC, founded in 2017 and headquartered in La Jolla, California. The LunaPBC team, investors, and advisors are renowned in the patient-advocacy, health, and science fields, including several former chief executives of Illumina, industry academics, and financial executives. Learn more at www.lunadna.com.
-
Category
- Health IT/Services
-
Status
- Private
-
Location
La Jolla, CA
-
Year Invested
2019
-
Team
-
-
Menlo Therapeutics Inc. (NASDAQ: MNLO) is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Learn more at www.menlotherapeutics.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Menlo Park, CA
-
Year Invested
2015
-
Team
-
-
NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. Learn more at www.nflectionrx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Cambridge, MA
-
Year Invested
2016
-
Team
-
-
Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including pain, cough and itch. Learn more at www.nociontx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Cambridge, MA
-
Year Invested
2019
-
Team
-
-
The migration of rapid, accurate molecular testing to “the edge” in point-of-care and at-home settings is becoming a foundational pillar of quickly evolving healthcare delivery strategies globally. Proof Diagnostics will contribute to this changing landscape by delivering CRISPR-based solutions, starting with a COVID-19 test, that are simple, rapid and affordable for everyone. Learn more at Proofdx.com.
-
Category
- MedTech
-
Status
- Private
-
Location
Cambridge, MA
-
Year Invested
2020
-
Team
-
-
Singular Genomics (NASDAQ: OMIC) is developing a new next generation sequencing platform. Learn more at www.singulargenomics.com.
-
Category
- MedTech
-
Status
- Public
-
Location
La Jolla, CA
-
Year Invested
2019
-
Team
-
-
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Learn more at www.tempesttx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
San Francisco, CA
-
Year Invested
2018
-
Team
-
-
Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Learn more at www.vervetx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Cambridge, MA
-
Year Invested
2019
-
Team
-
